Twenty-five years of the amyloid hypothesis of alzheimer disease: advances, failures and new perspectives

Close metadata

Recommended articles:

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Impact of metabolic parameters and risk factors on surfactant proteins SP-A and SP-D in abdominal obesity. Russian Journal of Preventive Medicine. 2024;(7):60-66

The role of astrocytes, circadian rhythms and light pollution in the pathogenesis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):20-25

Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):81-91

Insulin resistance as a cardiovascular risk factor in patients with ulcerative colitis. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):42-49

Amyloid hypothesis of Alzheimer’s disease (AD) has been long the primary one. During the 25-year history the concept has been dramatically changed. Accumulation of β-amyloid is associated not only with the disruption of its synthesis (as it seemed after the discovery of genetic mechanisms of some familial cases of AD) but rather with the disruption of its clearance and elimination from the brain tissue via the microcirculatory system. It has been recognized that soluble oligomers of β-amyloid, but not senile plaques that consisted of insoluble conjugates described by A. Alzheimer 100 years ago, play a key pathogenic role in the brain. Interrelation of vascular and degenerative processes is confirmed by common risk factors, clinical, neuroimaging, pathomorphological and experimental data. Insulin-resistance is also one of the links between AD degenerative and vascular processes. Based on the current state of the amyloid hypothesis, perspectives of new multimodal treatment strategies are discussed.

Keywords:

β-amyloid

Alzheimer’s disease

arteriosclerosis

insulin resistance

multimodal therapy

Authors:

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Vasenina E.E.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

List of references:

Selkoe D. Resolving controversies on the path to Alzheimer’s therapeutics. Nature Medicine. 2011;17(9):1060-1065. doi: 10.1038/nm.2460
Glenner G, Wong C. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications. 1984;120(3):885-890. doi: 10.1016/s0006-291x(84)80190-4
Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences. 1991;12:383-388. doi: 10.1016/0165-6147(91)90609-v
Selkoe D, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 2016. doi: 10.15252/emmm.201606210
Ikram M. Risk prediction of Alzheimer’s disease: An epidemiologic perspective. Alzheimer’s & Dementia. 2010;6(4):119-120. doi: 10.1016/j.jalz.2010.05.373
Luchsinger J, Reitz C, Honig L, Tang M, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer's disease. Neurology. 2005;65(4):545-551. doi: 10.1212/01.wnl.0000172914.08967.dc
Vermeer S, Prins N, den Heijer T, Hofman A, Koudstaal P, Breteler M. Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. New EnglandJournal of Medicine. 2003;348(13):1215-1222. doi: 10.1056/nejmoa022066
Reed B, Villeneuve S, Mack W, DeCarli C, Chui H, Jagust W. Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis. JAMANeurology. 2014;71(2):195. doi: 10.1001/jamaneurol.2013.5390
Rodrigue K, Rieck J, Kennedy K, Devous M, Diaz-Arrastia R, Park D. Risk Factors for β-Amyloid Deposition in Healthy Aging. JAMA Neurology. 2013;70(5):600. doi: 10.1001/jamaneurol.2013.1342
Barnes D, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology. 2011;10(9):819-828. doi: 10.1016/S1474-4422(11)70072-2
Snowdon D. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA: The Journal of the American Medical Association. 1997;277(10):813-817. doi: 10.1001/jama.277. 10.813
Honig L, Kukull W, Mayeux R. Atherosclerosis and AD: Analysis of data from the US National Alzheimer’s Coordinating Center. Neurology. 2005;64(3):494-500. doi: 10.1212/01.wnl.0000150886.50187.30
Dolan H, Crain B, Troncoso J, Resnick S, Zonderman A, OBrien R. Atherosclerosis, dementia, and Alzheimer’s disease in the BLSA cohort. Annals ofNeurology. 2010. doi: 10.1002/ana.22055
Zheng L, Vinters H, Mack W, Zarow C, Ellis W, Chui H. Cerebral Atherosclerosis Is Associated With Cystic Infarcts and Microinfarcts but Not Alzheimer Pathologic Changes. Stroke. 2013;44(10):2835-2841. doi: 10.1161/STROKEAHA.113.001945
Chui H, Zheng L, Reed B, Vinters H, Mack W. Vascular risk factors and Alzheimer’s disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther. 2011;3(6):36. doi: 10.1186/alzrt98
Toledo J, Arnold S, Raible K, Brettschneider J, Xie S, Grossman M, Monsell S, Kukull W, Trojanowski J. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain. 2013;136(9):2697-2706. doi: 10.1093/brain/awt188
Roher A. Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer’s Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(11):2055-2062. doi: 10.1161/01.atv.0000095973.42032.44
Beach T, Wilson J, Sue L, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor D, Sabbagh M, Walker D, Roher A. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathologica. 2006;113(1):13-21. doi: 10.1007/s00401-006-0136-y
Yarchoan M, Xie S, Kling M, Toledo J, Wolk D, Lee E, Van Deerlin V, Lee V, Trojanowski J, Arnold S. Cerebrovascular atherosclerosis correlates with Alzheimer"s pathology in neurodegenerative dementias. Brain. 2012;135(12): 3749-3756. doi: 10.1093/brain/aws271
Neltner J, Abner E, Baker S, Schmitt F, Kryscio R, Jicha G, Smith C, Hammack E, Kukull W, Brenowitz W, Van Eldik L, Nelson P. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain. 2013;137(1):255-267. doi: 10.1093/brain/awt318
Thomas T, Miners S, Love S. Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer’s disease and vascular dementia. Brain. 2015;138(4):1059-1069. doi: 10.1093/brain/awv025
Roher A, Garami Z, Tyas S, Maarouf C, Kokjohn T, Belohlavek M, Vedders L, Connor D, Sabbagh M, Beach T, Emmerling M. Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7(4):445-455. doi: 10.1016/j.jalz.2010.09.002
Hughes T, Kuller L, Barinas-Mitchell E, McDade E, Klunk W, Cohen A, Mathis C, DeKosky S, Price J, Lopez O. Arterial Stiffness and β-Amyloid Progression in Nondemented Elderly Adults. JAMA Neurology. 2014;71(5): 562. doi: 10.1001/jamaneurol.2014.186
Zhang X, Zhou K, Wang R, Cui J, Lipton S, Liao F, Xu H, Zhang Y. Hypoxia-inducible Factor 1 (HIF-1)-mediated Hypoxia Increases BACE1 Expression and beta-Amyloid Generation. Journal of Biological Chemistry. 2007;282(15):10873-10880. doi: 10.1074/jbc.m608856200
Tesco G, Koh Y, Kang E, Cameron A, Das S, Sena-Esteves M, Hiltunen M, Yang S, Zhong Z, Shen Y, Simpkins J, Tanzi R. Depletion of GGA3 Stabilizes BACE and Enhances β-Secretase Activity. Neuron. 2007;54(5):7 21-737. doi: 10.1016/j.neuron.2007. 05.012
Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Aβ generation by altering β- and γ-cleavage of APP. Neurobiology of Aging. 2009;30(7):1091-1098. doi: 10.1016/j.neurobiolaging.2007.10.011
Okamoto Y, Yamamoto T, Kalaria R, Senzaki H, Maki T, Hase Y, Kitamura A, Washida K, Yamada M, Ito H, Tomimoto H, Takahashi R, Ihara M. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathologica. 2011;123(3):381-394. doi: 10.1007/s00401-011-0925-9
Zetterberg H, Mörtberg E, Song L, Chang L, Provuncher G, Patel P, Ferrell E, Fournier D, Kan C, Campbell T, Meyer R, Rivnak A, Pink B, Minnehan K, Piech T, Rissin D, Duffy D, Rubertsson S, Wilson D, Blennow K. Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans. PLoS ONE. 2011;6(12):28263. doi: 10.1371/journal.pone.0028263
Faraco G, Park L, Zhou P, Luo W, Paul S, Anrather J, Iadecola C. Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. Journal of Cerebral Blood Flow & Metabolism. 2015. doi: 10.1038/jcbfm.2015.79
Iadecola C. Vascular and Metabolic Factors in Alzheimer’s Disease and Related Dementias. Cellular and Molecular Neurobiology. 2016;36:151-154. doi: 10.1007/s10571-015-0319-y
Niwa K, Kazama K, Younkin L, Younkin S, Carlson G, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283(1):315-323. doi: 10.1152/ajpheart.00022.2002
Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991;146(1):148-155. doi: 10.1002/jcp.1041460119
Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Archives of Gerontology and Geriatrics. 1989;9(2):181-192. doi: 10.1016/0167-4943(89)90038-1
Jacob S, Dietze GJ, Machicao F et al. Improvement of glucose metabolism in patients with type II diabetes after treatment with hemodialysate. Arzneimittelforschung. 1996;3:269-272.
Elmlinger M, Kriebel M, Ziegler D. Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. Neuromol Med. 2011;13(4):266-274. doi: 10.1007/s12017-011-8157-7
Dieckmann A, Kriebel M, Andriambeloson E, Ziegler D, Elmlinger M. Treatment with Actovegin improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes. 2011;120(3):132-138. doi: 10.1055/s-0031-1291248
Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci. 2012;322(1):222-227. doi: 10.1016/j.jns.2012.07.069
Donoghue J. Actovegin in the treatment of dementia: A systematic review and analysis of outcomes using the number needed to treat (NNT). Clin Pharmacol Ther. 2013;22(4):70-75.
Guekht A, Skoog I, Korczyn A, Zakharov V, Eeg M, Vigonius U. A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dement Geriatr Cogn Disord Extra. 2013;3(1):459-467. doi: 10.1159/000357122

Close metadata